Diorasis Therapeutics

Funding and NIH signals

• NIH award NIH awarded $759K (SBIR Phase II 1R44EY039191-01, new, notice Sep 17, 2026). NIH RePORTER 1R44EY039191-01 (Sep 17, 2026)
  Evidence (1 event)

  • Sep 17, 2026 · NIH RePORTER 1R44EY039191-01
    Organization: DIORASIS THERAPEUTICS CORPORATION; City/State: Watertown, MA; Project number: 1R44EY039191-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 758533; Administering IC: National Eye Institute; Project title: Gene therapy to normalize intraocular pressure for the treatment of juvenile open angle glaucoma; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals